Amdoxovir
From Wikipedia, the free encyclopedia
Amdoxovir
|
|
Systematic (IUPAC) name | |
[(2R,4R)-4-(2,6-Diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol | |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C9H12N6O3 |
Mol. mass | 252.23 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Amdoxovir is an nucleoside reverse transcriptase inhibitor (NRTI) undergoing research for the treatment of HIV. It is being developed by RFS Pharma.[1] Currently, it is in Phase II clinical studies.
[edit] References
- ^ AIDSmeds.com - Amdoxovir. Retrieved on 2008-03-21.
|